Aulos Bioscience raises $20 million in series A to further alternative IL-2 approach
August 21, 2023 | PDF 49KB
CEO Aron Knickerbocker speaks with BioWorld about the company’s $20 million Series A extension funding, the science behind AU-007 and the latest on its Phase 1/2 clinical study in solid tumor cancers.
Life Science Leader
Leading Aulos Bioscience’s “Triumvirate” Model
June 1, 2023
During an interview with Life Science Leader, CEO Aron Knickerbocker discusses Aulos’ commitment to maximizing the ingenuity of a balanced team and continuing development of AU-007, the company’s lead candidate.
IL-2 upgrades show promise at ASCO
July 13, 2022
Nature Biotechnology looks at IL-2 therapeutics, including AU-007 and its unique ability to bind to IL-2, blocking activation of trimeric receptors on Tregs and endothelial cells while stimulating effector T cells and NK cells.